Evidence map›Paper›PMID 30684048›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice.

Raffaele Giusti, Marco Mazzotta, Marco Filetti, Gennaro Daniele, Hiroaki Tsukuura, Corrado Ficorella, Giampiero Porzio, Paolo Marchetti, Lucilla Verna

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Raffaele GiustiMedical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Via di Grottarossa 1035-39, 00189, Rome, Italy. rgiusti@ospedalesantandrea.it.ORCID http://orcid.org/0000-0003-4592-8868
Marco MazzottaMedical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Via di Grottarossa 1035-39, 00189, Rome, Italy.
Marco FilettiMedical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Via di Grottarossa 1035-39, 00189, Rome, Italy.
Gennaro DanieleClinical Trials Unit, National Cancer Institute of Naples, Naples, Italy.
Hiroaki TsukuuraTokyo Sakura Hospital, 1-11-1 Higashishinosaki machi, Edogawa-ku, Tokyo, Japan.
Corrado FicorellaMedical Oncology, Department of Biotechnological and Applied Clinical Sciences, St. Salvatore Hospital, L'Aquila, Italy.
Giampiero PorzioMedical Oncology, Department of Biotechnological and Applied Clinical Sciences, St. Salvatore Hospital, L'Aquila, Italy.
Paolo MarchettiMedical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Via di Grottarossa 1035-39, 00189, Rome, Italy.
Lucilla VernaMedical Oncology, Department of Biotechnological and Applied Clinical Sciences, St. Salvatore Hospital, L'Aquila, Italy.
Azienda Ospedaliera Sant'Andrea · ITSan Salvatore Hospital · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAntiemetics are being used both for the treatment and prophylaxis of opioid-induced nausea and vomiting (OINV) in clinical practice, despite the lack of evidence for the prophylactic benefit. Studies among Japanese physicians demonstrated over 80% prescribe antiemetics, with neuroleptic antipsychotics as the most commonly prescribed drugs. Our objective was to elucidate the current scenario of the prophylactic use of antiemetics for OINV among Italian physicians.

methodsWe conducted a web-based cross-sectional national survey. All the invited participants received an e-mail with an 11-item electronic questionnaire accessible through a direct link. Anonymity was guaranteed. According to the exploratory intent of the survey, we did not predefine any formal statistical hypothesis. Associations between variables were tested by the Pearson chi-square or the Fisher exact test.

resultsFrom January to March 2017, 112 completed the electronic questionnaire (112/256, overall response rate, 43.7%). Nearly half of the participants were oncologists (54; 48.2%). Sixty-one (54.4%) physicians worked in palliative care units. About 45% of the interviewed prescribed prophylactic antiemetics at the beginning of opioid prescription. The most commonly chosen drugs for this purpose were prokinetics such as metoclopramide and domperidone (84%), followed by 5-HT3 antagonists (8%), neuroleptic antipsychotics (6%), and corticosteroids (2%). Ninety-one physicians (81%) declared to prescribe antiemetics at the occurrence of OINV, mainly prokinetics (N = 70; 77%).

conclusionItalian physicians do not commonly prescribe prophylactic antiemetics for OINV. Unlike previously reported data, dopamine antagonists resulted the most commonly prescribed drugs. Prospective clinical trials are necessary to evaluate the real efficacy of this practice.

Indexed as

Adrenal Cortex HormonesAdultAnalgesics, OpioidAntiemeticsAntipsychotic AgentsCross-Sectional StudiesDomperidoneDopamine AntagonistsFemaleHumansItalyLanguageMaleMetoclopramideNauseaPhysiciansAdrenal Cortex HormonesAnalgesics, OpioidAntiemeticsAntipsychotic AgentsDomperidoneDopamine AntagonistsMetoclopramideSerotonin 5-HT3 Receptor AntagonistsAntiemeticsCancer painOINVOpioid-induced nausea and vomitingProphylaxis

Identifiers

PMID30684048
OpenAlexW2914634677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.